This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.
Compared to Estimates, Avantor, Inc. (AVTR) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Avantor, Inc. (AVTR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Avantor, Inc. (AVTR) Q3 Earnings Meet Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 0% and 1.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity's (RVTY) New Launch to Widen Access to Editing Technology
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to improve access to new-generation editing technology and bridge both preclinical and clinical discoveries with the same technology platform.
Alignment Healthcare (ALHC) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alignment Healthcare (ALHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics
by Zacks Equity Research
Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.
New Strong Sell Stocks for September 11th
by Zacks Equity Research
AVTR, TECH and CPRI have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2023.
Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Revvity (RVTY) Down 4.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for August 22nd
by Zacks Equity Research
AVTR, BHLB and TECH have been added to the Zacks Rank #5 (Strong Sell) List on August 22, 2023.
Avantor (AVTR) Q2 Earnings Lag Estimates, FY23 View Revised
by Zacks Equity Research
Despite Avantor's (AVTR) strength in end markets, it reports an overall soft second-quarter performance.
Here's What Key Metrics Tell Us About Avantor, Inc. (AVTR) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Avantor, Inc. (AVTR) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Avantor, Inc. (AVTR) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of -3.45% and 3.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Avantor, Inc. (AVTR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avantor's (AVTR) New Expansion Plans to Boost Workflow
by Zacks Equity Research
Avantor's (AVTR) latest expansion plans are likely to aid customers in creating customized workflow solutions.
Strength Seen in Bright Health (BHG): Can Its 11.9% Jump Turn into More Strength?
by Zacks Equity Research
Bright Health (BHG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management
by Zacks Equity Research
Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.
Avantor, Inc. (AVTR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.57% and 0.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 27.45% and 1.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avantor, Inc. (AVTR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avantor, Inc. (AVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.
Centene (CNC) Q4 Earnings Miss on High Costs, '23 Premium View Up
by Zacks Equity Research
Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.